All subcategories » published RCT
Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial.
primary studies published RCT
Details- 2023
- Stahl M
A prospective randomised controlled mixed-methods pilot study of home monitoring in adults with cystic fibrosis.
primary studies published RCT
Details- 2022
- Nash EF
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.
primary studies published RCT
Details- 2023
- Mayer-Hamblett N
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele.
primary studies published RCT
Details- 2023
- Goralski JL
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.
primary studies published RCT
Details- 2023
- Wainwright C
A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR.
primary studies published RCT
Details- 2022
- Rayment JH
Evaluating the alginate oligosaccharide (OligoG) as a therapy for Burkholderia cepacia complex cystic fibrosis lung infection.
primary studies published RCT
Details- 2022
- Fischer R
Airway clearance physiotherapy and health-related quality of life in cystic fibrosis.
primary studies published RCT
Details- 2022
- Gursli S
Gut Bifidobacteria enrichment following oral Lactobacillus-supplementation is associated with clinical improvements in children with cystic fibrosis.
primary studies published RCT
Details- 2022
- Ray KJ
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3B, Randomized, Placebo-Controlled Study.
primary studies published RCT
Details- 2022
- Mall MA